Beijing Hotgen Biotech Co., Ltd. (688068.SH): SGC001 innovative drug's Phase Ib clinical data presented as a poster at the AHA

Beijing Hotgen Biotech Co., Ltd. (688068.SH) announced that recently, its controlled subsidiary Beijing Shunjing Biopharmaceutical Technology Co., Ltd. ("Shunjing Pharma") presented the Phase Ib clinical study data of SGC001 injection in a poster session at the American Heart Association (AHA) Scientific Sessions. SGC001 is an emergency-use monoclonal antibody drug developed jointly by the R&D team of Shunjing Pharma and the Beijing Institute of Heart, Lung and Blood Vessel Diseases, Beijing Anzhen Hospital, Capital Medical University. It is intended for emergency treatment of patients with acute myocardial infarction (AMI) (the first indication being developed is "anterior ST-segment elevation myocardial infarction"). Previously, for AMI, no related antibody drug had entered the clinical research stage or been approved for marketing. The Phase Ib clinical study presented at the AHA conference preliminarily verified the drug's good safety and tolerability, and positive exploratory efficacy signals were observed, providing strong support for subsequent R&D.